LONDON and NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced first patients enrolled…
Strategic collaboration with leading global contract research organization to implement randomized, double-blind, placebo-controlled Phase 2 study of novel neuroprotective therapy Strategic collaboration with leading global contract research organization to implement randomized, double-blind…
"Too many boots. Too many cats. I hope you can forgive me," the singer said.
Die weltweit einzige bekannte Prüftherapie in der klinischen Phase 3 zur Behandlung von SBMA AJ201 (Rosolutamid) ist ein in der Erprobung befindliches, oral verabreichtes niedermolekulares Präparat, das darauf abzielt, mehrere Krankheitsmechanismen der spinalen und bulbären Muskelatrophie...
From scouting character to ending the teardown, Washington Wizards GM Will Dawkins details the vision behind drafting AJ Dybantsa and how the franchise is finally shifting toward competitive growth.
CAMBRIDGE, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company leveraging its oligonucleotide promoted editing of RNA (OPERA ® ) platform to develop a new class of genetic medicines for rare and highly prevalent diseases…
The Chapter 11 case is playing out in New Jersey.
A 2026 study of 303 UK CFOs finds that the financial close puts heavy pressure on finance teams, yet account reliability, rather than close speed, remains the priority for 67% of finance leaders. The findings reframe what financial close automation software means for UK enterprises: automating…
Vial's IL-13 x TSLP is designed to deliver breadth, depth, and durability of Type 2 disease control in a single half-life-extended antibody Phase 1a data in healthy volunteers (15–800 mg IV) support progression into patients, with pharmacokinetics that could support twice-yearly (Q6M)...
